Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents

Álvarez, Beatriz; Arcos, Javier; Fernández-Guerrero, Manuel L.

doi:10.1097/mcp.0b013e3283455c0b

Cited by 17 publications

(12 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-TNF is currently being used to treat human inflammatory and autoimmune diseases, for example, rheumatoid arthritis. Use of this drug has been associated with decreased immune responses to a variety of pathogens [ 48 , 49 ].…”

Section: Discussionmentioning

confidence: 99%

Immunological Response to Single Pathogen Challenge with Agents of the Bovine Respiratory Disease Complex: An RNA-Sequence Analysis of the Bronchial Lymph Node Transcriptome

et al. 2015

View full text Add to dashboard Cite

Susceptibility to bovine respiratory disease (BRD) is multi-factorial and is influenced by stress in conjunction with infection by both bacterial and viral pathogens. While vaccination is broadly used in an effort to prevent BRD, it is far from being fully protective and cases diagnosed from a combination of observed clinical signs without any attempt at identifying the causal pathogens are usually treated with antibiotics. Dairy and beef cattle losses from BRD are profound worldwide and genetic studies have now been initiated to elucidate host loci which underlie susceptibility with the objective of enabling molecular breeding to reduce disease prevalence. In this study, we employed RNA sequencing to examine the bronchial lymph node transcriptomes of controls and beef cattle which had individually been experimentally challenged with bovine respiratory syncytial virus, infectious bovine rhinotracheitis, bovine viral diarrhea virus, Pasteurella multocida, Mannheimia haemolytica or Mycoplasma bovis to identify the genes that are involved in the bovine immune response to infection. We found that 142 differentially expressed genes were located in previously described quantitative trait locus regions associated with risk of BRD. Mutations affecting the expression or amino acid composition of these genes may affect disease susceptibility and could be incorporated into molecular breeding programs. Genes involved in innate immunity were generally found to be differentially expressed between the control and pathogen-challenged animals suggesting that variation in these genes may lead to a heritability of susceptibility that is pathogen independent. However, we also found pathogen-specific expression profiles which suggest that host genetic variation for BRD susceptibility is pathogen dependent.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunological Response to Single Pathogen Challenge with Agents of the Bovine Respiratory Disease Complex: An RNA-Sequence Analysis of the Bronchial Lymph Node Transcriptome

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Tuberculosis and other bacterial diseases, together with influenza, as well as diseases caused by respiratory syncytial viruses, human metapneumovirus, parainfluenza virus, adenoviruses and coronaviruses, can cause life threatening conditions in healthy people. Even otherwise harmless infections can cause complications in patients with pre-existing lung diseases such as asthma, COPD, bronchiectasis, cystic fibrosis, or primary immunodeficiencies, and other conditions that alter immunologic mechanisms against microbial invasion [229]. Susceptibility to infection as well as onset, duration and severity of symptoms is controlled by dynamic and patient-specific host-microbe interactions which, in addition to the rise in antibiotic resistance, has contributed to the difficulty of developing effective treatments [230][231][232].…”

Section: Pulmonary Infectious Diseasementioning

confidence: 99%

Stem cell-based Lung-on-Chips: The best of both worlds?

Nawroth

Barrile

Conegliano

et al. 2019

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Pathologies of the respiratory system such as lung infections, chronic inflammatory lung diseases, and lung cancer are among the leading causes of morbidity and mortality, killing one in six people worldwide. Development of more effective treatments is hindered by the lack of preclinical models of the human lung that can capture the disease complexity, highly heterogeneous disease phenotypes, and pharmacokinetics and pharmacodynamics observed in patients. The merger of two novel technologies, Organs-on-Chips and human stem cell engineering, has the potential to deliver such urgently needed models. Organs-on-Chips, which are microengineered bioinspired tissue systems, recapitulate the mechanochemical environment and physiological functions of human organs while concurrent advances in generating and differentiating human stem cells promise a renewable supply of patient-specific cells for personalized and precision medicine. Here, we discuss the challenges of modeling human lung pathophysiology in vitro, evaluate past and current models including Organs-on-Chips, review the current status of lung tissue modeling using human pluripotent stem cells, explore in depth how stem-cell based Lung-on-Chips may advance disease modeling and drug testing, and summarize practical consideration for the design of Lung-on-Chips for academic and industry applications.

show abstract

“…The presently available data suggest a subtle increase in the risk of infection in association with rituximab. However, concomitant immunosuppressive therapies and disease‐associated immune dysregulation make the causal attribution of infections problematic: A meta‐analysis in patients with rheumatoid arthritis reported that the overall odds ratio for serious infections under rituximab was not significantly increased (OR 1.45; 95% CI: 0.56‐3.73), and in another meta‐analysis of rituximab utilisation in clinical practice, anti‐CD20 therapy was associated with a significantly lower odds of serious infections relative to other biologics …”

Section: Depletion Of Cd20+ B Cellsmentioning

confidence: 99%

Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors

Kyriakidis

Tragiannidis

Zündorf

et al. 2017

Mycoses

View full text Add to dashboard Cite

An expanding list of immunomodulatory or immunosuppressive monoclonal antibodies (mAbs) and biologic therapeutics is currently entering clinical practice, particularly in the areas of oncology, transplantation and autoimmune disorders. These agents are directed against molecules or cells involved in inflammation and immunity and may therefore be associated with serious and opportunistic infections. The purpose of this review was to critically analyse the literature on invasive fungal infections (IFIs) occurring in association with mAbs and fusion proteins other than tumour necrosis alpha (TNF-α) inhibitors, including therapeutics modulating T-cell-mediated pathologies (muromonab, abatacept, belatacept, ipilimumab, basiliximab, daclizumab), inducing lymphopenia (alemtuzumab), depleting CD20+ B cells (rituximab) and interfering with various targets (anakinra, natalizumab, blodalumab, ixekizumab and others) with a focus on children, and to provide a framework of evaluating the risk for IFIs in this population.

show abstract

Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents

Cited by 17 publications

References 40 publications

Immunological Response to Single Pathogen Challenge with Agents of the Bovine Respiratory Disease Complex: An RNA-Sequence Analysis of the Bronchial Lymph Node Transcriptome

Immunological Response to Single Pathogen Challenge with Agents of the Bovine Respiratory Disease Complex: An RNA-Sequence Analysis of the Bronchial Lymph Node Transcriptome

Stem cell-based Lung-on-Chips: The best of both worlds?

Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors

Contact Info

Product

Resources

About